It is estimated that 1–3% of NSCLC cases with adenocarcinoma histology exhibit BRAF mutations, with approximately half having BRAF V600E mutations resulting in a constitutively active BRAF kinase. This evidence concerns the gene BRAF and adenocarcinoma.